Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SCD1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SCD1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SCD1 Products |
| Selectivity Panel A | SCD2 Recombinant Protein For counter-screening vs SCD2 (paralog). |
View SCD2 Products |
| Selectivity Panel B | SCD5 Recombinant Protein For counter-screening vs SCD5 (CNS safety). |
View SCD5 Products |
| Gene Delivery | SCD1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines; preserves native ER membrane conformation. |
View SCD1 Products |
| Benchmark Ab | Anti-SCD1 Control Antibody Recombinant positive control for assay benchmarking. |
View SCD1 Products |
| Validator | SCD1 siRNA Set For knockdown verification and specificity checks. |
View SCD1 Products |
| Pathway Partner A | FASN (Fatty Acid Synthase) Upstream lipogenesis pathway convergence. |
View FASN Products |
| Pathway Partner B | GPX4 Lipid peroxidation regulator; SCD1 inhibition sensitizes cells to ferroptosis. |
View GPX4 Products |
| Selectivity Control | ACLY (ATP-Citrate Lyase) Cytosolic acetyl-CoA generation node. |
View ACLY Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass ER membrane protein conformation | Lentivirus Premade Particles for stable cell line generation; ensures native folding & lipid environment. |
| Isoform selectivity (SCD1 vs SCD2/SCD5) | Homolog panel proteins strictly verified by mass spec; SCD2 and SCD5 recombinant proteins available. |
| Enzymatic activity screening | NADH-binding domain structurally preserved; cytochrome b5 reductase compatible. |
| Cellular lipid phenotype | Stable cell line lentivirus for desaturation index (16:1/16:0) quantification. |
| Lack of positive controls | Recombinant Benchmark Antibodies for reproducible IHC/WB standard curves. |
| Target engagement false positives | Sequence-verified siRNA included for precise genetic knockdown specificity checks. |
Live SCD1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SCD1 therapeutics is intensifying, with major players shifting focus from broad systemic modulation to tissue-specific targeting. Historical systemic inhibition caused sebaceous gland toxicity (e.g., Novartis, Merck), leading to program terminations. Next-generation strategies include: (1) liver-targeted small molecules and siRNA for MASH/NASH, (2) topical inhibitors for dermatological/ophthalmic indications (e.g., Aramis Biosciences' dry eye disease program), and (3) combination regimens triggering ferroptosis in solid tumors (e.g., SCD1 + GPX4 synergy). The field is also leveraging prodrug strategies and tissue-specific delivery to avoid CNS side effects while maximizing hepatic efficacy.
Key mutation noted in dbSNP rs2234970 (UniProt O00767 VAR_025994) is associated with altered SCD1 activity; this variant is relevant for genetic association studies and patient stratification in metabolic and cancer trials.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need |
|---|---|---|---|
| Small Molecule (Systemic) | Novo Nordisk, Eli Lilly, DIA Ventures | NASH, NAFLD, Obesity | Enzyme kinetics (high-purity SCD1 protein) |
| siRNA/Liver-targeted | Arrowhead, Silence Therapeutics | Refractory NASH | Gene knockdown validation (siRNA controls) |
| Topical Small Molecule | Aramis Biosciences, Yuhan | Dry Eye Disease, Acne | Topical penetration & cellular assays (lentivirus for sebocyte models) |
| Cancer Metabolism (Ferroptosis) | Xinthera, Academic Consortia | Prostate, Breast, Solid Tumors | Synergy screening (WT vs mutant protein/siRNA panels) |
Molecular Differentiation & Assay Strategy
To develop a Best-in-Class SCD1 inhibitor, the following differentiation factors must be addressed:
- Tissue-specific delivery: For NASH, liver-selective prodrugs or siRNA conjugates to minimize systemic exposure. For cancer, tumor microenvironment accumulation.
- Isoform selectivity: SCD1 vs SCD2 (>100-fold for metabolic safety) and SCD5 (CNS safety). Panel screening using SCD2 and SCD5 recombinant proteins.
- On-target inhibition kinetics: Partial or reversible inhibition may be preferred to avoid ER stress overactivation. Allosteric modulators targeting dimer interface are emerging.
- Mutation awareness: The rs2234970 missense variant (Val293Met) in SCD1 affects enzyme stability; inclusion in selectivity panels supports patient stratification.
Recommended Assays:
- Enzymatic activity: NADH oxidation rate using purified SCD1 (with cytochrome b5 reductase).
- Cellular desaturation index: GC/MS of 16:1/16:0 and 18:1/18:0 ratios in HepG2 cells overexpressing SCD1.
- Isoform counter-screen: IC50 determination against SCD2 and SCD5.
- Ferroptosis synergy: Co-treatment with GPX4 inhibitor (e.g., RSL3) and viability readout.
TarMart solutions: High-purity recombinant SCD1/SCD2/SCD5 proteins, lentivirus for stable cell lines, and validated siRNA sets — enabling rigorous selectivity, activity, and synergy screening.